Dual-Pathway Combination Therapy for Multifactorial Affective Disorders
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for brain and behavioral health disorders, such as anxiety, depression, and psychosis, are limited in effectiveness as they typically target only a single component of the disorder, failing to address the multi-factorial nature of these conditions, leading to untreated neurological underpinnings and disabling symptoms.
Innovation Solution
A combination therapy using agents that target the adrenergic system (e.g., verapamil) and the renin angiotensin aldosterone system (e.g., telmisartan) to modulate stress-induced hormones in the body and brain, promoting equilibration of cerebral blood flow and addressing the multi-factorial aspects of these disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current FDA-approved treatments (SSRIs, cognitive behavioral therapy) are used to target single components of brain and behavioral health disorders, then specific symptoms may be partially addressed, but the multi-factorial nature of these disorders remains untreated, leading to limited treatment effectiveness
Solution Approach 1:
The patent combines two previously separate treatment approaches (adrenergic system targeting and RAAS system targeting) into a unified treatment regimen. This merging allows simultaneous addressing of multiple disorder components through a coordinated dual-targeting strategy, thereby improving overall treatment effectiveness while maintaining manageable complexity through systematic integration
2Adaptability or versatility
If targeted single-component treatments are applied to brain and behavioral health disorders, then specific neurological or psychological aspects may be addressed, but the interconnected multi-factorial causes remain untreated
Solution Approach 1:
The patent creates a universal treatment framework that simultaneously addresses multiple disorder components (neurological, psychiatric, and psychological factors) through a dual-targeting approach. This multi-functional treatment design allows a single regimen to cover diverse symptomatology across different disorder types, enhancing adaptability while managing complexity through standardized protocol integration
3Reliability
If combination therapy targeting both adrenergic system and renin angiotensin aldosterone system is implemented, then multi-factorial aspects of brain and behavioral health disorders are addressed, but treatment complexity increases
Solution Approach 1:
The patent segments the complex treatment approach into two distinct but coordinated components: adrenergic system targeting and RAAS system targeting. This segmentation allows each component to be optimized and monitored independently while maintaining their synergistic relationship, thereby managing treatment complexity through structured division of therapeutic functions
Data Source
AI summary
As described below, the present invention features compositions and methods for treating brain and/or behavioral health disorders and their associated symptoms.